Swiss National Bank Trims Stake in Intellia Therapeutics, Inc. $NTLA

Swiss National Bank reduced its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 1.2% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 187,400 shares of the company’s stock after selling 2,300 shares during the period. Swiss National Bank owned 0.18% of Intellia Therapeutics worth $1,332,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Cambridge Investment Research Advisors Inc. lifted its holdings in shares of Intellia Therapeutics by 51.7% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 19,726 shares of the company’s stock valued at $140,000 after purchasing an additional 6,722 shares during the last quarter. D.A. Davidson & CO. lifted its holdings in shares of Intellia Therapeutics by 76.2% in the 1st quarter. D.A. Davidson & CO. now owns 26,020 shares of the company’s stock valued at $185,000 after purchasing an additional 11,250 shares during the last quarter. California State Teachers Retirement System lifted its holdings in shares of Intellia Therapeutics by 4.1% in the 4th quarter. California State Teachers Retirement System now owns 90,638 shares of the company’s stock valued at $1,057,000 after purchasing an additional 3,596 shares during the last quarter. Baker BROS. Advisors LP purchased a new stake in shares of Intellia Therapeutics in the 4th quarter valued at about $7,510,000. Finally, Deutsche Bank AG lifted its holdings in shares of Intellia Therapeutics by 12.1% in the 4th quarter. Deutsche Bank AG now owns 252,501 shares of the company’s stock valued at $2,944,000 after purchasing an additional 27,282 shares during the last quarter. 88.77% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on NTLA. Wells Fargo & Company restated an “overweight” rating and issued a $45.00 price target (down previously from $50.00) on shares of Intellia Therapeutics in a research report on Friday, August 8th. HC Wainwright dropped their price target on Intellia Therapeutics from $30.00 to $25.00 and set a “buy” rating on the stock in a research report on Friday, August 8th. Citigroup dropped their price target on Intellia Therapeutics from $14.00 to $10.00 and set a “neutral” rating on the stock in a research report on Friday, May 9th. Canaccord Genuity Group dropped their price target on Intellia Therapeutics from $74.00 to $54.00 and set a “buy” rating on the stock in a research report on Tuesday, June 3rd. Finally, Guggenheim restated a “buy” rating and issued a $14.00 price target on shares of Intellia Therapeutics in a research report on Wednesday, August 13th. Twelve research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Intellia Therapeutics has an average rating of “Moderate Buy” and an average price target of $29.05.

Intellia Therapeutics Trading Up 8.2%

NASDAQ NTLA opened at $11.38 on Tuesday. The business’s 50 day moving average is $11.13 and its two-hundred day moving average is $9.53. Intellia Therapeutics, Inc. has a 12-month low of $5.90 and a 12-month high of $24.05. The stock has a market capitalization of $1.22 billion, a price-to-earnings ratio of -2.43 and a beta of 2.31.

Intellia Therapeutics (NASDAQ:NTLA) last released its earnings results on Thursday, August 7th. The company reported ($0.99) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.03) by $0.04. Intellia Therapeutics had a negative return on equity of 57.48% and a negative net margin of 908.48%.The company had revenue of $14.25 million for the quarter, compared to analysts’ expectations of $12.26 million. During the same quarter in the previous year, the firm posted ($1.52) EPS. The firm’s quarterly revenue was up 104.3% on a year-over-year basis. Equities analysts forecast that Intellia Therapeutics, Inc. will post -5.07 earnings per share for the current fiscal year.

Insider Activity at Intellia Therapeutics

In other news, Director William J. Chase purchased 100,000 shares of the stock in a transaction that occurred on Wednesday, August 20th. The shares were acquired at an average price of $10.03 per share, for a total transaction of $1,003,000.00. Following the acquisition, the director directly owned 134,693 shares in the company, valued at approximately $1,350,970.79. The trade was a 288.24% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Edward J. Dulac III sold 7,462 shares of the company’s stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $14.02, for a total value of $104,617.24. Following the completion of the sale, the executive vice president owned 106,062 shares in the company, valued at approximately $1,486,989.24. This represents a 6.57% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 12,534 shares of company stock worth $153,837 in the last quarter. 3.10% of the stock is currently owned by insiders.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.